Cilengitide TFA 是一种选择性的 αvβ3和 αvβ5受体整合素抑制剂，IC50分别为 4 nM 和 79 nM。对 GP IIb/IIIa 的选择性约为 10 倍。

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

6-Thio-dG induces telomere dysfunction and results in progressive telomere shortening in telomerase-positive human cancer cells and hTERT-expressing human fibroblasts. In tested cancer cells, 6-thio-dG inhibits cell viability with IC50 values between 0.7 and 2.9 μM. [1]

199807-35-7

C29H41F3N8O9

702.689

Ethanol:<1 mgml
H2O:8 mg/mL (11.38 mM)
DMSO:93 mg/mL (132.4 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years